Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.95 4.43% 46.00 347,665 16:12:04
Bid Price Offer Price High Price Low Price Open Price
45.10 46.00 46.00 45.00 45.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.51 -9.78 -13.36 32
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:16 O 200,000 45.00 GBX

Oncimmune (ONC) Latest News

More Oncimmune News
Oncimmune Investors    Oncimmune Takeover Rumours

Oncimmune (ONC) Discussions and Chat

Oncimmune Forums and Chat

Date Time Title Posts
26/11/202207:18Oncimmune (ONC) cancer test diagnoses '80pc of tumours' early, savin251
23/1/201807:49Oncimmune (ONC) could save millions of lives2
20/2/200100:30Online Classics plc1

Add a New Thread

Oncimmune (ONC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:03:1445.00200,00090,000.00O
16:35:1646.002,5001,150.00UT
16:05:2846.002,000920.00AT
16:05:2846.003,0001,380.00AT
16:05:2846.005,0002,300.00AT
View all Oncimmune trades in real-time

Oncimmune (ONC) Top Chat Posts

Top Posts
Posted at 26/11/2022 07:18 by brummy_git
There are 2 golden rules when investing in nascent healthcare stocks.

Find out here what they are & potentially how to profit from these secular tailwinds.

www.linkedin.com/posts/paul-hill-a5994116_vrci-llai-onc-activity-7002167778723950592-M7p9?utm_source=share&utm_medium=member_desktop

Posted at 05/10/2022 07:42 by brummy_git
Marvellous long term future ahead for Oncimmune, a global leader in all things auto-antibody & immunodiagnostics.

Find out here why from CEO Adam Hill & Chairman Alistair Macdonald.

www.linkedin.com/posts/paul-hill-a5994116_video-qa-with-oncimmune-ceo-dr-adam-m-activity-6983329490898714625-lwvh?utm_source=share&utm_medium=member_desktop

Posted at 24/9/2022 03:31 by 40 fathoms
@rambutan2

Yes, I think you are right this is a key pharagraph, but once again I think it suffers from their communication style which would benefit from being more explicit. I also think there is a mistake in the announcement, the cash margin requirement is a covenant to demonstrate (tested on quarterly basis) they have at least 9 months forward cash flow on hand, it is not at a rate of 9%.

I would have presented more like this

Gross Cash

31 May 2021 - 8.63 million
30 Nov 2021 - 2.79 million
31 May 2022 - 2.53 million

Net Debt

31 May 2021 - 0.53 million
30 Nov 2021 - 5.93 million
In Dec 2021 - Company drew down an additional 2.5 million from facility to finance expansion of US BD team
31 May 2022 - 8.16 million

I am afraid my hackles are always raised when I see the levels of interest and fees that IPF and their ilk are able to charge but when you think about it rationally I would rather pay them that and some warrants than be diluted and paying similar levels of cash to a broker.

The headroom is there to sign and convert contracts in to cashflow, this year is now all about execution. The RNS flow on new contract announcements over the next 6 months (which is seasonally the strong period) will be the key leading indicator and if we get positive and early RNS flow we should see the share price move up very substantially.

Posted at 19/3/2022 03:37 by 40 fathoms
A recent spotlight on ONC from Luminex who are a key partner for us given their XMAP technology.

hTtps://www.luminexcorp.com/blog/luminex-licensed-technologies-partner-spotlight-oncimmune/

Posted at 28/2/2022 21:17 by rambutan2
https://uk.advfn.com/stock-market/london/oncimmune-ONC/share-news/Oncimmune-Holdings-PLC-Contract-signed-with-Verily/87401065

hTTps://verily.com/covid19/

Posted at 15/2/2022 08:51 by brummy_git
More encouraging contract news today from immunodiagnostics firm Oncimmune

Find out what this means here.

www.linkedin.com/posts/paul-hill-a5994116_onc-onc-onc-activity-6899259635661164544-T6I-

Posted at 02/11/2021 08:01 by pugugly
Not (imo) encouraging finance-wise
"The revenue reported is lower than the headline £5.6M indicated in the unaudited full-year trading update issued on 8 June, due largely to revenue recognition relating to an invoice for £1.7M to an historic EarlyCDT Lung distributor. The Group is unable to recognise this revenue in the year ended 31 May 2021 as the revenue recognition requirements of IFRS 15 have not been met at this time"

https://www.investegate.co.uk/oncimmune-hldngs-plc--onc-/rns/full-year-results-and-progress-update/202111020700080071R/

However encouraging progress with technology adopters -

Posted at 05/5/2021 08:40 by someuwin
N + 1 Singer...

Oncimmune Holdings (ONC LN)

Life Sciences Current price* 238.0p

China EarlyCDT rights returned

Oncimmune is to reacquire the China and Hong Kong rights to the EarlyCDT product portfolio from Genostics. The decision was made to provide strategic optionality removing a potential conflict that may have existed if Oncimmune were to access the US capital markets. The immediate financial impact of removing EarlyCDT Lung royalties in China is modest, and we have decreased our revenue estimates by 2.8% and 4.9% in FY’22 and FY’23, respectively. This decision leaves the door open for future value-creating partnerships in China, but importantly, our investment hypothesis, where we anticipate strong growth and commercial traction for the ImmunoINSIGHTS platform, remains unchanged. We continue to view Oncimmune as a Best Idea for 2021, and the next scheduled update is a post-period end trading statement expected in early June...

Posted at 05/5/2021 06:56 by someuwin
Zeus Capital

Oncimmune

ONC LN Biotechnology

Reacquisition of IP and distribution rights for Chinese lung cancer test

Oncimmune has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to complete in H1 2021, with regulatory filing to follow shortly afterwards. We would expect the company to be in advanced discussions with a new licensee/ distributor or acquirer of the geographically-specific test, and that a new licensing agreement or divestment will be net value accretive. We maintain our positive outlook for Oncimmune, based on expectations of strong revenue growth and profitability. Valuation and current forecasts are under review pending an update by a new analyst.

Oncimmune has announced that it is reacquiring the IP and distribution rights for its EarlyCDT┬« lung cancer diagnostic in the Peoples Republic of China and Hong Kong, originally licensed to the Genostics Company Limited in January 2018. As part of the original deal Genostics made a £10m equity investment in Oncimmune. Genostics currently holds than less than a 5% share in Oncimmune. The cost of reacquisition has not been disclosed, and as such are likely to be relatively nonmaterial (i.e. < £1m).

Since January 2018 Oncimmune and Genostics have been developing a lung cancer test with superior performance given the high prevalence rates of EGFR +ve non-small cell lung cancer in the China and Asia-Pacific regions. The test uses an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells that are specific to Asian populations.

In May 2019 Oncimmune announced that the new test had entered a new multicentre case control study, in the People’s Republic of China assessing early detection of lung cancer, study approximately 1,000 early lung cancers at five leading academic health centres across China. The study is due to complete in H1 2021, with the data for the newly validated panel used to support approval of the test by Chinese regulators (the China National Medical Products Administration).

Oncimmune has been actively pursuing a new licensing partner for EarlyCDT┬« in China, and we would be surprised if, given that regulatory filing is likely before midmid, the company was not in advanced discussions with either a new licensee, or even a potential acquirer. We would expect a new licensing agreement or divestment to be net value accretive. We note that a reduced dependency on China as part of overall corporate strategy may be beneficial given Oncimmune’s intention. Going forwards, to increase its focus on the US, both in terms of operations and capital markets. We maintain a positive outlook on the stock, although our valuation and current forecasts are currently under review pending an update by a new analyst."

Posted at 05/5/2021 06:15 by someuwin
5 May 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Return of China Rights to EarlyCDT product portfolio

Enables strategic optionality to support access to the US capital markets

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT (R) technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory.

Since granting Genostics the exclusive rights to EarlyCDT products in the PRC and HK in January 2018, Oncimmune and Genostics have collaborated to develop a lung panel with superior performance in Greater China and Asia-Pacific, given the prevalence of EGFR-positive non-small cell lung cancer (NSCLC) in the region. The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC.

Under the agreement announced today, all material, IP, data, and goodwill will be transferred back to the Company, and Oncimmune will be paid in full for the royalties due in January 2021 under the existing Technology Licencing Agreement. In consideration, Oncimmune has agreed to pay a fixed amount for the return of the IP and distribution rights, with the majority of the value of the consideration being conditional on fixed future events.

With accelerating growth of Oncimmune's ImmunoINSIGHTS business, the Company intends to explore options available to it to access the US capital markets in the near term. The termination of Oncimmune's partnership with Genostics and return of the EarlyCDT product rights to the PRC and HK markets provides Oncimmune with further strategic optionality which could support a path to the US capital markets.

As part of the agreement, and as previously announced, Genostics has agreed to a lock-in of its remaining shareholding in Oncimmune (currently 4.73 per cent. of the issued share capital) for a period of 12 months from 6 May 2021, except under certain limited exceptions.

Dr Adam M Hill, CEO of Oncimmune said: " We are grateful for the collaboration with Genostics and its parent company, Gene Group Holdings Ltd, over the past three years and are pleased with the progress that has been made with our Asia-specific lung panel. However, as both companies consider their future on different equity capital markets, the continuing success of the EarlyCDT product portfolio, both in and outside of PRC and HK, requires Oncimmune to own the IP and distribution rights. We are delighted that Genostics has agreed to continue to participate in Oncimmune's success as a shareholder, and Oncimmune looks forward to progressing its market access plans imminently."

Oncimmune share price data is direct from the London Stock Exchange
Your Recent History
LSE
ONC
Oncimmune
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221129 22:37:09